Early results of a safety and efficacy study of allogeneic TruUCAR (TM) GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
CANCER RESEARCH(2022)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
CANCER RESEARCH(2022)